Cargando…

Anti-PD-1, anti-VEGF, and temozolomide therapy in a patient with recurrent glioblastoma: a case report

BACKGROUND: Patients suffering from postoperative recurrent glioblastoma have an extremely unfavorable outcome because there are no proven therapeutic options. The median overall survival for those with relapsed glioblastoma after surgery is only 7.5 months. Case presentation: Between March 2015 and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Can, Zuo, Wenwei, Yang, Pan, Zhang, Yanling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479856/ https://www.ncbi.nlm.nih.gov/pubmed/32883128 http://dx.doi.org/10.1177/0300060520951395

Ejemplares similares

A rare case report of recurrent atypical meningioma with multiple metastases treated with anti-PD-1 and anti-VEGF therapy
por: Zhao, Jia-Li, et al.
Publicado: (2022)

VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma
por: Martini, Maurizio, et al.
Publicado: (2018)

Neoadjuvant anti-PD-1 immunotherapy for recurrent glioblastoma
por: Mitchell, Dana, et al.
Publicado: (2019)

Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma
por: Daniel, Paul, et al.
Publicado: (2022)

Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: A case report
por: Alshami, Jad, et al.
Publicado: (2015)

Tumor Recurrence in a Glioblastoma Patient after Discontinuation of Prolonged Temozolomide Treatment
por: Tseng, Wei-Lung, et al.
Publicado: (2017)

Irradiation or temozolomide chemotherapy enhances anti-CD47 treatment of glioblastoma
por: Gholamin, Sharareh, et al.
Publicado: (2019)

Case Report: Complete Remission With Anti−PD−1 and Anti−VEGF Combined Therapy of a Patient With Metastatic Primary Splenic Angiosarcoma
por: Xu, Weiran, et al.
Publicado: (2022)

Revisiting anti-angiogenic therapy for recurrent glioblastoma
por: Peters, Katherine B.
Publicado: (2019)

Efficacy of temozolomide and bevacizumab for the treatment of leptomeningeal dissemination of recurrent glioblastoma: A case report
por: OKITA, YOSHIKO, et al.
Publicado: (2015)

The remote effects of intravitreal anti-VEGF therapy
por: Balta, F, et al.
Publicado: (2016)

A case of anti-VEGF therapy application in Takayasu arteries with retinopathy
por: Gong, Qiaoyun, et al.
Publicado: (2020)

Long-term efficacy and safety of anti-VEGF therapy in retinitis pigmentosa: a case report
por: Miyata, Manabu, et al.
Publicado: (2018)

SDF-1 Blockade Enhances Anti-VEGF Therapy of Glioblastoma and Can Be Monitored by MRI()()
por: Deng, Lei, et al.
Publicado: (2016)

ET-12 ANTI-VEGF THERAPY WITH KETOGENIC DIET AGAINST GLIOBLASTOMA IN MOUSE MODEL
por: Sasayama, Takashi, et al.
Publicado: (2019)

Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma
por: Fujimaki, Takamitsu, et al.
Publicado: (2007)

Pazopanib and anti-VEGF therapy
por: Drabkin, Harry A
Publicado: (2010)

Continuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patients
por: Wang, Yu, et al.
Publicado: (2017)

Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma
por: Ge, Jingjing, et al.
Publicado: (2021)

The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy
por: Pożarowska, Dorota, et al.
Publicado: (2016)

Angiosarcoma treated successfully with anti-PD-1 therapy - a case report
por: Sindhu, Simran, et al.
Publicado: (2017)

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
por: Strobel, Hannah, et al.
Publicado: (2019)

A Phase I Trial of VEGF-A Inhibition Combined with PD-L1 Blockade for Recurrent Glioblastoma
por: Chiu, Daniel, et al.
Publicado: (2023)

Lenvatinib or anti-VEGF in combination with anti–PD-1 differentially augments antitumor activity in melanoma
por: Tran, Thuy T., et al.
Publicado: (2023)

ET-02 EFFICACY OF THE SALVAGE THERAPY VIA LOMUSTINE AND NIMUSTINE FOR RECURRENT GLIOBLASTOMA WITH TEMOZOLOMIDE RESISTANCE
por: Yamamuro, Shun, et al.
Publicado: (2019)

Anti-VEGF in a Marathon Runner's Retinopathy Case
por: Soon, Alexander Kahjun, et al.
Publicado: (2016)

Continuous Low-Dose Temozolomide Chemotherapy and Microvessel Density in Recurrent Glioblastoma
por: Woo, Jong-Yun, et al.
Publicado: (2015)

Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide
por: Faustino, Alexandre Ciuffi, et al.
Publicado: (2020)

Apatinib Plus Temozolomide for Recurrent Glioblastoma: An Uncontrolled, Open-Label Study
por: Wang, Yong, et al.
Publicado: (2019)

Anti-VEGF Therapy and the Retina: An Update
por: Tah, Vikas, et al.
Publicado: (2015)

Tumor refractoriness to anti-VEGF therapy
por: Ribatti, Domenico
Publicado: (2016)

Anti-VEGF therapy for central retinal vein occlusion caused by tuberculosis-associated uveitis: a case report
por: Taguchi, Manzo, et al.
Publicado: (2017)

Efficiency of anti‐VEGF therapy in central nervous system AML relapse: A case report and literature review
por: Cao, Han‐Yu, et al.
Publicado: (2022)

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
por: Heynckes, Sabrina, et al.
Publicado: (2019)

Temozolomide resistance in glioblastoma multiforme
por: Lee, Sang Y.
Publicado: (2016)

Successful Treatment of pMMR MSS IVB Colorectal Cancer Using Anti-VEGF and Anti-PD-1 Therapy in Combination of Gut Microbiota Transplantation: A Case Report
por: Cheng, Xianshuo, et al.
Publicado: (2023)

Individual recurrence intervals after anti-VEGF therapy for age-related macular degeneration
por: Hörster, Robert, et al.
Publicado: (2010)

Rapid symptomatic and structural improvement of a retinal astrocytic hamartoma in response to anti-VEGF therapy: A case report
por: Allan, Kevin C., et al.
Publicado: (2022)

Acute macular neuroretinopathy associated with intravitreal anti-VEGF injection: A case report
por: Radwan, Loubna M., et al.
Publicado: (2022)

Apatinib combined with temozolomide treatment for pseudoprogression in glioblastoma: A case report
por: Zhao, Mingming, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_satgpsbeo2p19lnavtt2b29et2